IRADIMED CORPORATION (IRMD) News
Follow IRADIMED CORPORATION (IRMD) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
iRadimed Q3'26 Earnings Preview: EPS Estimate at 0.55
iRadimed is scheduled to report Q3'26 results on October 30 before the market opens. Revenue is estimated at 23.47 million USD, with EPS expected at 0.55 USD.
EQUITY | Oct 29, 2026, 11:01 AM UTC
L
IRMD - IRADIMED CORPORATION To Participate in the 5th Annual ROTH Healthcare Opportunities Conference
IRMD - IRADIMED CORPORATION To Participate in the 5th Annual ROTH Healthcare Opportunities Conference
NEWS | Sep 23, 2026, 01:01 PM UTC
L
iRadimed Raises FY2026 Adj EPS Guidance from $2.06-$2.21 to $2.09-$2.24 vs $2.08 Est; Raises FY2026 Sales Guidance from $91.000M-$96.000M to
iRadimed (NASDAQ: IRMD ) raises FY2026 Adj EPS guidance from $2.06-$2.21 to $2.09-$2.24 vs $2.08 analyst estimate. Raises FY2026 sales outlook from $91.000 million-$96.000 million to $91.000 billion-$96.000 billion vs $9
EARNINGS | Jul 31, 2026, 12:16 PM UTC
L
IRMD Iradimed RESULTS: Q2, Q2 REV $20.5M, Q2 EPS $0.41
IRMD Iradimed RESULTS: Q2, Q2 REV $20.5M, Q2 EPS $0.41
EARNINGS | Jul 31, 2026, 12:15 PM UTC
L
IRMD - IRADIMED CORPORATION Reports Second Quarter 2026 Financial Results
IRMD - IRADIMED CORPORATION Reports Second Quarter 2026 Financial Results
EARNINGS | Jul 31, 2026, 12:15 PM UTC
L
Iradimed Corporation (IRMD) Sales Reflects The Fund’s Valuation and Sizing Discipline
Iradimed Corporation (IRMD) Sales Reflects The Fund’s Valuation and Sizing Discipline
EQUITY | Jul 27, 2026, 02:10 PM UTC